Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.

INTRODUCTION

Mechanisms of DNA damage detection, response, and repair are critical to preserving genomic integrity and preventing malignancy. Depending on the mechanism of DNA damage and lesion formation, the DNA-damage response (DDR) is achieved by various sensor, signaling, and effector proteins.[ 1 , 2 ] DNA single-strand break (SSB) damage is remedied by three main pathways: base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR). The more severe DNA double-strand breaks (DSBs) are resolved by two major DSB repair pathways: homologous recombination (HR) and nonhomologous end-joining (NHEJ).[ 1 , 2 ] Alterations of these the DDR and replication stress (RS) pathways result in unchecked replicative immortality, accumulation, and propagation of additional genetic abnormalities by bypassing physiologic checkpoints, which ultimately leads to cancer development. As our understanding of the complexity of DDR signaling as well as the interplay of these pathways with other cellular processes grows, so too does the list of potential therapeutic targets and strategies to exploit DDR vulnerabilities in tumor cells.

Whole-exome and transcriptome analysis has empowered the goal of precision medicine by enabling specific biomarker-driven treatment strategies based on a tumor's dependency, including DNA repair network deficiencies.[ 3 ] In the setting of DNA repair pathway defects, increased dependence on remaining intact repair pathways is necessary for cancer cell survival and proliferation, providing an avenue to therapeutically exploit DNA repair deficiencies for cancer treatment. The most successful therapeutic example includes the use of poly(ADP-ribose) polymerase inhibitors (PARPi), which typify a synthetic lethal approach for the treatment of cancers with compromised ability to repair double-strand DNA breaks by HR, including those with defects in BRCA1/2.[ 4 – 6 ]

In response to DNA damage, DDR pathway mediators regulate immunoregulatory signaling,[ 7 ] potentially affecting the balance between tumor progression and immune surveillance, with potential implications for immunotherapy utility and outcomes. The interplay between defective DSB repair proteins or therapeutic use of DDR inhibitors and accumulation of chromosomal abnormalities, higher tumor mutational burden (TMB), oncogene activation, and tumorigenesis has also been shown to alter immunologic vulnerability. More specifically, dysfunctional DDR has the potential to augment immune recognition, activate immunostimulatory genes, increase tumor infiltrating lymphocytes (TILs), and antitumor immune production of interferon (IFN)-γ with resultant immunosuppressive tumor programmed death-ligand 1 (PD-L1) upregulation.[ 8 – 12 ] Similar effects can be observed as a result of genomic stress induced by DNA-damaging treatments, including radiation therapy (RT) and platinum-based chemotherapies. This may occur in part as the result of chromosomal fragments that stimulate the cytosolic sensing cGAS/STING pathway, promoting antitumor immunity through activation of T and natural killer (NK) cells and neoantigen recognition. [12–16]. These pathways will be discussed later in this review.

Going forward, understanding the specific mutational, transcriptional, and immunologic profiles of individual malignant processes is critical in rational use of therapeutic interventions that target susceptible components of DDR and antitumor immunity. Because precision medicine approaches are now an important arsenal in standard of care cancer treatment, we explore genomic and transcriptomic alterations in cancer, how these may be therapeutically exploitable, challenging mechanisms of resistance and the growing data on the relationship between DDR targeting and immunotherapy to inform novel combination treatment strategies.

Overview of DDR and Repair Signaling

Cells accumulate DNA damage as the result of stochastic mutational kinetics and cytotoxic stress, and DDR is central to the recognition and downstream repair of SSBs and DSBs. DDR accomplishes this by arresting proliferation and allowing for repair or facilitating removal of damaged cells through activation of senescence or apoptosis. Cancer cells often contain abnormal DDR signaling and RS machinery that contributes to oncogenesis by increasing DNA damage and genomic instability[ 17 ] and this often increases reliance on alternate error-prone repair pathways. This may present as an increased susceptibility to DNA-damaging therapies and DDR inhibition.

Progression of DDR signaling is dependent on the specific type of DNA damage, where numerous proteins are involved in interconnected repair pathways: BER, NER, and MMR pathways are responsible for repairing SSBs, and HR and NHEJ pathways participate in the more severe DSB repair. A multitude of DNA damage sensors, effectors, and transducers enact DDR mechanisms. Ataxia telangiectasia mutated (ATM), ATM- and RAD3-related (ATR), and DNA-dependent protein kinase (DNA-PK) act as core regulators of DDR signaling ( Figure 1 ). Following DNA damage, sensor proteins and complexes directly recognize DNA structure and recruit ATM, ATR, and DNA-PK to strand breaks; examples of these include poly(ADP-ribose) polymerases-1 and -2 (PARP1/2), H2AX, Ku70/880, and MRN (MRE11/RAD50/NBS1). PARP1/2 are important DNA-damage sensors and regulators of BER-mediated SSB repair, as well as other DDR pathways including a prospective role in DSB repair.[ 18 , 19 ] The Ku complex, which is composed of Ku70 and Ku80 subunits, also mediates DSB repair albeit via more distinct and antagonistic mechanisms than that of PARPs. Binding of PARPs to DSBs promotes alt-EJ, whereas Ku complex binding recruits and activates the DNA-PK catalytic subunit, resulting in NHEJ. As such, competition between PARP1 and Ku complex binding at DSBs is an important biologic concept determining DDR with therapeutic implications. The MRN complex is a DNA sensor that can also bind DNA ends resulting in recruitment and activation of ATM. ATM and ATR protein kinases, operating together via downstream targets checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), respectively, play a vital role in DDR signaling by maintaining replication fork stability and the regulation of cell cycle control checkpoints.[ 20 ] ATM is the primary kinase accountable for phosphorylation of H2AX, an early step in recruitment of DDR mediators. DNA-PK activity is required for NHEJ, and the WEE1 nuclear kinase regulates mitotic entry and nucleotide reservoirs during DNA damage response.[ 20 ]

Loss of function mutations in crucial genes involved in DDR and cell cycle checkpoints, such as BRCA1/2, ATM, ATR, CHEK1/2, BRD4, PTEN, or TP53, can result in impaired removal of genome mutations, accumulation of DNA damage, and increases the risk of oncogenesis.[ 21 ] Mutational data analysis across major tumor types supports this; for example, TP53, ATM, and ATR are highly mutated in bladder cancer (50%, 11.2%, and 4.1%), lung adenocarcinoma (51.8%, 7.9%, and 5.7%), and colorectal adenocarcinoma (58.6%, 5.7%, and 2.1%, respectively).[ 3 ] In men who develop metastatic castration-resistant prostate cancer (mCRPC), approximately a quarter have a mutation in DNA repair genes, with the most common mutated genes being BRCA2 (44%), ATM (13%), CHEK2 (12%), and BRCA1 (7%).[ 22 ] Tumor cells persist despite these barriers to genomic fidelity and cell proliferation by activating alternate repair pathways in response to DDR deficiency, thereby counteracting sensitivity to lethal genomic insult by preventing cytotoxic stress and perpetuating oncogenesis. As a result of tumor cells often harboring oncogenic defects in DDR pathways and therefore having increased dependence on alternate DDR mechanisms to survive, there is an opportunity to exploit these dependencies by targeting the DNA repair pathways that lead to subsequent accumulation of lethal levels of DNA damage as compared with normal cells. For example, tumor cells with deficiencies in HRR pathways have reduced ability to repair DNA DSBs. Mutations in HRR components, such as BRCA1/2, PALB2, and ATM renders the repair pathway ineffective, resulting in homologous recombination-deficiency (HRD) and precise therapeutic exploitation ( Figure 1 ). This creates a synthetic lethal interaction with inhibition of PARP1, which has been successful in the clinic.

DNA RS also closely interconnects with DDR signaling. Tumor cell hyperproliferation and associated oncogenic RS leads to replication fork stall and collapse with resultant accumulation of SSBs and DSBs, single-strand DNA (ssDNA), and ultimately multifaceted ATR-dependent response to maintain genomic stability. ATR is a key protein kinase involved in RS-response and plays important roles in cell cycle checkpoints and can mediate DNA DSB repair through HRR. ATR signaling activates an S/G2 cell cycle checkpoint, where unrepaired DNA damage can be resolved before entering mitosis through G2 cell cycle checkpoint activation. The protein tyrosine kinase WEE1 plays dual roles in cell cycle progression involving both S-phase and G2/M checkpoints.[ 23 ] Defects in or inhibition of G2 checkpoint signaling permits cells with unrepaired DNA damage to enter mitosis prematurely, resulting in cell death. Many cancer cells exhibit an increased dependence on S and G2 DNA damage checkpoints as the result of irregular TP53 activity, which would otherwise stop G1 checkpoint signals. Ongoing DNA damage in cancer cells in the setting of DDR deficiencies therefore provides potential therapeutic opportunities that may overwhelm these correction mechanisms.

Therapeutically Targeting Tumor-associated DDR and Repair

Two well-studied HR repair pathway defects are mutations in BRCA1 and BRCA2, with germline variants initially discovered in patients with hereditary breast or ovarian cancer, which have provided the basis for HRD therapeutic targeting. However, somatic and germline BRCA1/2 mutations as well as alterations in other HR genes, such as ATM, ATR, CHK1, CHK2, PALB2, RAD51, BARD1, and FANC, are increasingly recognized by next-generation sequencing (NGS) techniques across tumor types.[ 24 ] These aberrations, which are not typically present in normal cells, may be therapeutically exploitable, particularly in combination with DNA damage-targeting therapies.[ 25 ] A preeminent goal of precision oncology is to identify these specific defects and dependencies and use targeted DDR inhibitors to selectively optimize cancer cell lethality.

PARP Inhibitors

One such important therapeutic approach that exploits DDR defects is the use of inhibitors of the (PARP) enzymes. These enzymes bind via zinc finger domains to SSBs via co-factor nicotinamide (β-NAD+) and catalyze the synthesis of PARP chains (auto-poly [ADP-ribosylation]), resulting in activation of intracellular signaling pathways that enable chromatin remodeling and recruitment of DDR-related protein machinery to prevent lethal accumulation of SSBs.[ 4 , 26 ] PARPi prevents DNA SSB repair and traps PARPs onto DNA. Normal cells with intact DDR signaling and salvage HR repair pathways demonstrate little or no toxicity to PARP inhibition.[ 4 , 6 , 27 , 28 ] However, in tumor cells with HRD, the combination of an endogenous genetic defect, such as HR deficiency, with PARP inhibition leads to unrepaired DSBs and collapsed replication forks and ultimately tumor cell death ( Figure 1 ). This concept is termed synthetic lethality .[ 6 ]

Inhibition of PARP is a successful biomarker-driven therapeutic approach. Numerous PARPi have been developed, including olaparib, rucaparib, niraparib, talazoparib, and veliparib for patients with BRCA1/2 mutant or HR-deficient cancers.[ 5 , 28 – 30 ] Other strategies to exploit HR include inducing synthetic lethality by generating a BRCAness phenotype, including preclinical studies using combinations with inhibitors of epidermal growth factor receptor (EGFR), PI3K, BET, and others.[ 31 – 33 ] We recently reported promising results of a clinical trial with lapatinib and veliparib in non-BRCA1/2 mutated triple-negative breast cancer (TNBC) based on an induced DNA repair deficiency with EGFR inhibition (ClinicalTrials.gov Identifier: NCT02158507 ).[ 34 ]

Ovarian cancer

To date, three agents—olaparib, rucaparib, and niraparib—are currently approved in different therapeutic settings for ovarian cancer based on the results of multiple clinical trials demonstrating improved progression-free survival (PFS) ( Table 1 ).[ 35 , 36 ] Although the most significant clinical benefit is seen in patients with germline BRCA1/2 mutations, clinical trials have demonstrated intermediate and modest benefit in patients with BRCA1/2 -wild-type HRD tumors and in patients without detectable HRD, respectively. Based on data from these trials, olaparib, niraparib, and rucaparib are US Food and Drug Administration (FDA) approved independent of BRCA1/2 status in the maintenance setting for patients with ovarian cancer. Apart from BRCA1/2 mutations, biomarkers that predict response to PARPi in ovarian cancer include RAD51C and RAD51D mutations, presence of HRD [as defined by high degree of locus-specific loss of heterozygosity (LOH)], and high-level BRCA1 promoter methylation.[ 37 ] PARPi monotherapy also has demonstrated clinical benefit for selected patients with ovarian cancer harboring deleterious or suspected deleterious germline and/or somatic BRCA1/2 mutation with disease progression or relapse following prior chemotherapy.[ 35 , 36 , 38 – 40 ] Talazoparib and veliparib are currently in late-phase trials in patients with newly diagnosed ovarian cancer ( Table 2 ).

Breast cancer

For breast cancer, olaparib and talazoparib are FDA approved as single-agent regimens for previously chemotherapy-treated, HER2 negative, metastatic breast cancers with germline BRCA mutations based on clinical trials demonstrating increased median PFS (and less toxicity as compared with conventional chemotherapy) ( Table 1 ). Maintenance olaparib for 1 year is now recommended following the completion of local treatment and (neo)adjuvant chemotherapy for patients with high-risk TNBC with germline BRCA1/2 mutations; pathogenic or likely pathogenic variants based on trials demonstrated significantly longer survival free of invasive or distant disease.[ 41 ] Trials of other PARPi in combination with alkylating agents are currently under way for advanced or metastatic TNBC[ 42 , 43 ] ( Table 2 ). The phase 2 and 3 PARTNER trial of neoadjuvant olaparib in combination with carboplatin followed by the standard chemotherapy is under investigation in patients with TNBC and/or germline BRCA mutations ( NCT03150576 ). Biomarker analyses from clinical trials have established a BRCA1ness gene signature as a significant predictive biomarker of response to neoadjuvant combination veliparib and carboplatin,[ 44 ] but additional trials are needed to better identify patients with PARPi-sensitive cancers.

Prostate cancer

On the heels of the PROfound trial, the FDA approved olaparib for the treatment of mCRPC with deleterious or suspected deleterious germline or somatic HRR gene mutations based on reduced risk of disease progression or death.[ 45 ] Interestingly, post hoc analysis examined the impact of prior chemotherapy and revealed a greater overall survival (OS) benefit among taxane-naïve patients with a BRCA1 or BRCA2 alteration, and conversely a greater OS benefit among taxane-experienced patients with ATM and cyclin dependent kinase 12 (CDK12) alterations. The phase 2 TOPARP-A and TOPARP-B trials reported that olaparib has activity against mCRPC with HRR defects, particularly BRCA2 homozygous deletions, biallelic loss of PALB2, and loss of ATM.[ 46 – 48 ]

The PARPi rucaparib is also approved for patients with mCRPC with germline or somatic BRCA mutations based on findings from the phase 2 TRITON2 trial, in which PARP inhibition improved objective response rate and a confirmed prostate-specific antigen (PSA) response.[ 49 ] Responses were also observed in patients with alterations in the DDR genes PALB2, FANCA, BRIP1, and RAD51B; interestingly, rucaparib has not shown responses in mCRPC with ATM, CDK12, or CHK2 alterations.[ 50 , 51 ] The TRITON3 randomized phase 3 confirmatory study has almost completed accrual ( NCT02975934 ).

In preliminary results from the TALAPRO studies, the PARPi talazoparib has demonstrated favorable antitumor activity in heavily pretreated patients with mCRPC and HRR gene alterations, most commonly BRCA1/2 mutations.[ 52 ]

Loss of function of other tumor suppressor DDR proteins, which are involved in HR, such as RAD51, ATR, ATM, CHK1, CHK2, FANCA, BRIP1, and partner and localizer of BRCA2 (PALB2), also have been shown to permit sensitization to PARPi.[ 26 , 53 ] These findings support the potential that PARPi might be a useful therapeutic strategy not only for the treatment of BRCA-mutated tumors but also for the treatment of a wider range of non–BRCA-mutated tumors that are inherently HRD or “BRCAness/HRDness.”[ 4 , 51 , 54 ]

Many active clinical trials are investigating PARPi in DDR-deficient malignancies, as well as in combination with radiotherapy, hormone therapy, chemotherapy, and immunotherapies ( Tables 2 – 4 ).

Gastrointestinal cancers

In patients with BRCA1/2-mutated pancreatic cancer, olaparib monotherapy has demonstrated modest benefits in PFS[ 38 , 55 ] ( Table 1 ); these benefits resulted in FDA approval in the maintenance treatment for germline BRCA-mutated advanced pancreatic adenocarcinoma that had not progressed on platinum-based chemotherapy. These results have opened opportunities to study combination strategies with PARPi.[ 56 ] In gastric cancers, BRCA1/2 mutations are uncommon. However, more frequent loss of ATM expression as measured by immunohistochemistry has served as rationale for PARPi therapy.[ 24 ] Promising phase 2 clinical trial data reported that olaparib plus paclitaxel versus placebo plus paclitaxel resulted in longer OS durations, and patients with low baseline levels of tumor ATM protein expression had the greatest benefit. However, the phase 3 GOLD trial of the same regimen did not meet its primary end point of improved OS in the olaparib-treated group, in neither the overall population nor an ATM-low subpopulation,[ 57 ] suggesting that factors outside of ATM loss influence PARPi response in gastric cancer, highlighting that single-gene or single-protein biomarker approaches might be inadequate.[ 58 ] Use of PARPi in patients with other gastrointestinal malignancies or with other DDR defects such as ATM, PALB2, and CHEK2 are ongoing ( Table 2 ). As our knowledge of other specific tumor cell DDR abnormalities and the interplay with other cellular processes increases, synthetic lethality approaches targeting DDR proteins, perhaps in multimodality combinations, will likely become more prevalent.

Resistance to PARP Inhibition

Despite biomarker-driven use of PARPi, limited response and durability suggests mechanisms of innate and/or acquired resistance to single-agent therapy. Patients with BRCA1/2-mutant cancers have experienced the most durable responses based on long-term clinical trial data, yet most even initially responsive patients develop resistance. Initial sensitivity and development of resistance likely is dependent on the restoration of HR repair capacity though activation of redundant DDR signaling activity, secondary mutations, or alterations in DDR mediators such as BRCA1/2, RAD51C, RAD51D, and PALB2. Furthermore, activation of oncogenic signaling pathways that slow cell cycle progression and subsequent , mitigation of RS via replication fork stabilization, as well as DDR pathway-independent mechanisms potentially contribute to therapeutic resistance.[ 24 ] Acquired resistance via BRCA reversion mutations must also be considered as a key resistance mechanism to both platinum-based chemotherapies and PARPi.[ 59 ] Many cancer cells also exhibit an increased dependence on S and G2 DNA damage checkpoints as the result of irregular p53 signaling that would otherwise stop G1 checkpoint signals. As such, therapeutic inhibition of S and G2 checkpoint components, including ATR, ATM, CHK1, CHK2, and WEE1, represent a hopeful anticancer strategy, and specific agents are actively being investigated. Studies so far have provided insight into mechanisms of resistance to PARPi; however, a better understanding of adaptive DDR responses and interconnectedness with other oncogenic pathways is required to overcome both innate and acquired resistance, and to expand therapeutic potential of DDR inhibitors.

Innate PARPi resistance may result from decreased inhibitor binding to PARP and DNA trapping as the result of mutations or loss of PARP1 expression.[ 46 , 60 ] Innate resistance may also be caused by increased PARP1 auto-PARylation, subsequent release of PARP from DNA and restoration of PARP signaling, and decreased PARPi-induced DNA damage as the result of endogenous deficiency in PAR glycohydrolase (PARG) activity.[ 61 ]

BRCA and RAD51c promoter methylation are positive predictive biomarkers for sensitivity to PARPi, whereas a single unmethylated gene copy is sufficient to confer resistance.[ 62 , 63 ] Exome analyses performed on primary tumor biopsy as well as on metastatic sites of disease revealed de novo TP53 mutations; analyses also showed increased frequencies of preexisting TP53 mutations compared with primary tumors, suggesting that TP53 status may be associated with PARPi resistance in the presence of BRCA mutations.[ 64 ] Genome-wide mutagenic screens also identified full-length and point mutations of PARP1 that cause in vitro and in vivo PARPi resistance.[ 60 ]

From these studies it is clear that current biomarkers of PARPi resistance are numerous and diverse, suggesting presence of tissue- and variant-dependent mechanisms of response and resistance that require further investigation. Precision approaches to combinatory strategies targeting molecular susceptibilities to thwart acquired resistance may also enhance and prolong DDR inhibitor response. In support of targeted combinatory strategies, NGS profiling of sensitive and resistant cell lines has revealed that oncogenic pathway activation (e.g., RAS, PI3K, or androgen receptor signaling) may promote HR repair activity and PARPi resistance in certain contexts.[ 65 – 67 ] Another study demonstrated that the ALK kinase inhibitor ceritinib synergizes with PARPi by attenuating complex I of the mitochondrial electron transport chain, which resulted in increased production of reactive oxygen species and subsequent induction of oxidative DNA damage that is repaired in a PARP-dependent manner. Combination of ceritinib and PARPi in this study was synergistic irrespective of HR status, and induced tumor regression more effectively than olaparib alone in high-grade serous ovarian carcinoma patient-derived xenografts.[ 68 ]

OTHER PROMISING DDR PATHWAY TARGETS

Ataxia telangiectasia mutated (ATM) and ATM- and RAD3-related (ATR)

ATR and ATM protein kinases, operating together via downstream targets CHK1 and CHK2, respectively, play vital roles in DDR signaling by maintaining replication fork stability and the regulation of cell cycle control checkpoints.[ 20 ] It is increasingly understood that functional crosstalk following DNA damage exists between ATM, ATR and the NHEJ-mediator DNA-PKs such that impaired function of these mediators represents a therapeutic opportunity for synthetic lethality. ATM is the key kinase involved in phosphorylation of histone H2AX on serine 139 (γH2AX), signifying DNA damage. Although hundreds of downstream substrates of ATM have been identified, fundamentally, activation of CHK2 is vitally involved in G1-S-phase checkpoint activation.[ 69 ] ATM also participates in stabilization of p53 through the phosphorylation and subsequent inhibition of proteasomal degradation by MDM2.[ 69 ] ATM and ATR both cooperate in the process of DSB repair during ionizing radiation (IR) or genotoxic stress. However, ATM is principally involved in response to DSBs, whereas ATR is primarily activated by SSBs; for example, ATM inhibition has been shown to hypersensitize tumor cells to IR and DNA DSB-inducing chemotherapeutics.[ 19 ] Emphasizing its role in DSBs repair and interconnectedness of DDR pathways, ATM, along with nuclease activity or Mre11, is required to generate the replication protein A–coated ssDNA needed for ATR recruitment and CHK1 activation during S and G2 cell cycle phases.[ 69 ] ATM deficiency in cancer is not uncommon, with mutations found in many solid tumors. ATR inhibitors are an emerging DDR-targeting strategy for cancers with HRDness, including deleterious ATM and BRCA1/2 mutations, and have been shown in early-phase trials to confer sensitivity to ATR inhibitor regimens.[ 24 ] ATR and ATM are potential targets of DDR inhibitors under increasing preclinical and clinical investigation ( Table 3 ).

ATM Deficiency and Enhanced Sensitivity to PARP Inhibition

ATM deficiency or inactivation has been shown to increase sensitivity to PARPi in preclinical models ( Figure 1 ).[ 3 ] The rationale for PARPi use in HRD cancers historically extends from the high sensitivity and synthetic lethality observed in BRCA1/2-mutant tumors; however, ATM deficiency also results in HRDness and is thought to promote dependence on alternate DDR mechanisms.[ 19 ]

In support, favorable response rates to olaparib were observed in a phase 2 trial for patients with prostate cancer that had progressed on prior standard treatments and who had defects in DDR genes such as BRCA1/2, ATM, or CHEK2.[ 46 – 48 ] It remains unclear what contribution ATM deficiency plays to PARP sensitivity in this setting, especially in the context of BRCA1/2 or other HRD-related gene mutations. This notion is supported by findings from the TRITON2 trial, which suggests ATM and CDK12 mutations confer less benefit from rucaparib as compared with BRCA1/2 loss in patients with mCRPC.[ 51 ]

However, limited responses to single-agent PARPi even in BRCA1/2-mutant tumors and unexpected response in non-HRD tumors suggest that innate or acquired resistance may potentially be overcome by pairing of PARPi with other DDR inhibitors, including ATR inhibitors.[ 3 ] For example, olaparib monotherapy has demonstrated limited clinical benefit (40% response rate, following first-line chemotherapy) in recurrent BRCA1/2-mutant high-grade serous ovarian carcinomas, despite relatively high frequency of HR repair gene defects.[ 3 ] The addition of ATR inhibitors to PARPi, however, has shown increased efficacy as compared with PARPi alone in early trials of BRCA-mutant ovarian cancer, suggesting that PARPi increases the dependence on ATR activity for fork stabilization.

DNA-dependent protein kinase (DNA-PK)

DNA-PK is a key enzyme involved in the NHEJ pathway of DNA repair.[ 19 ] As a member of the PI3K–mammalian target of rapamycin (mTOR) enzyme family, DNA-PK also plays a vast role in cell survival and proliferation and has emerged as an interesting therapeutic target in the treatment of a variety of cancers, especially when used along with genotoxic chemotherapy or IR where NHEJ is a fundamental repair mechanism.

The putative effects of DNA-PK inhibitors to sensitize tumor cells to chemotherapy and IR has also been pursued in clinical trials. M3814 (nedisertib) is being tested in multiple trials including along with IR therapy in advanced solid tumors ( NCT02516813 ). The DNA-PK pathway modulator CC-122 is being tested in multiple myeloma, advanced solid tumors, and non-Hodgkin's lymphoma ( NCT01421524 ). CC-115, a dual DNA-PK and mTOR inhibitor, is in phase 2 studies to determine its efficacy in mCRPC and along with IR for glioblastoma ( NCT02977780 ). M9831 is being tested in a phase 1 study with or without doxorubicin in patients with advanced-stage solid tumors ( NCT02644278 ).

Checkpoint Kinase 1 and 2

The downstream substrates of ATR and ATM, CHK1 and CHK2, respectively, are central cell cycle checkpoint kinases that coordinate with interconnected DDR pathways. Many early investigatory CHK1 and CHK2 inhibitors were not developed further in large part given associated toxicities particularly in combination with chemotherapy.[ 70 – 72 ] Although selectivity, poor efficacy, and toxicity have hindered advancement of many of these inhibitors in early-phase clinical trials, efficacy has been promising in specific settings. For instance, a patient with ATM-deficient small cell lung cancer (SCLC) and a RAD50-mutation experienced a complete response to the combination of irinotecan and AZD7762.[ 73 ]

The second-generation CHK1-selective inhibitor prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma. Prexasertib-induced radiosensitization was tested in a phase 1b trial of patients with locally advanced head and neck squamous cell carcinoma (SCC) in combination with cetuximab-radiotherapy.; This study showed this regimen to be safe and resulted in 83.3% overall response rates with several complete responses.[ 74 ] Prior concern regarding toxicity, particularly in the combination therapy setting, as well as appropriate patient selection, remain challenges for CHK1/2 inhibitors.[ 75 ] These studies highlight the need for combination strategies with nonoverlapping toxicity profiles to foster hope for CHK1/2 inhibitor efficacy. Ongoing clinical trials of selective CHK1/2 inhibitors are ongoing, including prexasertib (LY2606368), GDC-575 (ARRY-575; RG7741), and CCT245737 (SRA737). Prexasertib is currently being tested in clinical trials for metastatic TNBC ( NCT04032080 ), small round cell tumors, and rhabdomyosarcoma ( NCT04095221 ), in combination with cyclophosphamide or gemcitabine in medulloblastoma ( NCT04023669 ). GDC-575 ( NCT01564251 ) and CCT245737 ( NCT02797964 and NCT02797977 ) are in phase 1 testing as single agents or in combination with gemcitabine-based chemotherapy.

WEE1 Nuclear Kinase

WEE1, which is overexpressed and associated with outcomes across tumor types including glioblastoma and ovarian and breast cancer, activates G2/M cell cycle checkpoint by inhibiting CDK1/2, resulting in cell cycle arrest and procession of DNA damage repair. Avoidance of G2 checkpoint initiation by WEE1 inhibition results in premature mitotic entry, increased RS, and potentially lethal genomic instability. WEE1 inhibition can impair HR via CDK1-mediated phosphorylation of BRCA1 and BRCA2 .[ 76 ] It follows then that tumor cells with increased reliance on G2 checkpoints may be more susceptible to WEE1 inhibitor-induced G2 arrest and synthetic lethality by causing cells with unrepaired DNA damage to enter into mitosis and undergo mitotic catastrophe.[ 77 ]

Use of the WEE1 inhibitor, adavosertib (AZD1775; MK-1775), selectively inhibits the G2 checkpoint and lowers the threshold for mitotic lethality by sensitizing p53-deficient cells to genotoxic stressors such as chemotherapy and IR.[ 78 , 79 ] Adavosertib is currently in clinical development for patients with tumors harboring p53 mutations, specifically as a part of combinatory strategies with DNA-damaging treatments such as PARPi, chemotherapy, and IR.[ 80 ] Ongoing clinical studies evaluating WEE1 inhibitors in combination with other DDR inhibitors, chemotherapy, and/or IR in for multiple cancer types are ongoing[ 80 ] ( Tables 3 and 4 ).

DDR Signaling as a Mediator of Antitumor Immunity and Immunotherapy Response

Immune evasion is a hallmark of cancer that is the result of complex tumor-host immunological interactions, in part directed by aberrant tumor immunologic signaling and adaptive mechanisms that avoid immune surveillance and elimination.[ 17 ] Co-inhibitory cell surface receptors that regulate T-cell function, such as CTLA-4 and PD-1, are expressed in the tumor environment in response to T-cell activation. The balance between co-stimulatory and co-inhibitory signals is crucial for cytotoxic T-cell activation and immunologic tolerance.[ 81 ] Tumors can exploit this balance through co-inhibitory receptor engagement, for example via tumor PD-L1 expression and/or upregulation, to escape T-cell–mediated tumor rejection. Immune checkpoint inhibitors (ICIs) are used to therapeutically target these co-inhibitor signals and are capable of unleashing antitumor activity.[ 82 ] ICIs, including monoclonal antibodies against PD-1 (pembrolizumab, nivolumab), PD-L1 (atezolizumab, durvalumab, avelumab), and CTLA-4 (ipilimumab), have generated durable responses across many tumor types.

Although tumor cell PD-L1 expression is the best predictor of response to anti-PD-1/PD-L1 therapies, it is increasingly clear that many other factors, including intact IFN-γ signaling, TMB, MMR deficiency, and even DDR alterations can play significant roles in patient response to ICIs.[ 8 , 12 , 83 – 86 ] Indeed, numerous studies have shown crosstalk between DDR and many immune-related outcomes, including PD-L1 expression ( Figure 2 ).[ 87 – 89 ] By extension, clinical use of anti-PD-1/anti-PD-L1 monoclonal antibodies in mismatch repair-deficient tumors, for example, supports the notion that increasing tumor mutational load with DDR inhibitors may result in enhanced tumor cell immunogenicity and ICI response.[ 85 ]

Intact DDR signaling is important for innate immunity, activation of inflammatory cytokines, and expression of immune-receptor ligands on damaged tumor cells; in some instances the signaling can be used to predict ICI response.[ 90 ] Dysfunctional DDR signaling can elicit antitumor immune activation, supporting use of DDR biomarkers for ICI response and combinatory treatment strategies with DDR inhibitors and ICIs.[ 90 ] Highly mutated tumors often exhibit one or several mutations in key components of DDR or replicative pathways, including MSH2 for MMR/MSI, BRCA1/2 for HR, and polymerase epsilon (POLE) for DNA replication. Furthermore, targeting of DSB repair proteins with DDR inhibitors has also been shown to increase the TMB.[ 91 ] DDR-defect-dependent genomic instability, chromosomal fragmentation, and increased TMB can result in immune recognition, activation of immunostimulatory genes, increased TIL, and antitumor immune production of IFN-γ.[ 9 – 12 ] Generation of chromosomal fragments stimulates the cytosolic sensing cGAS/STING pathway that promotes antitumor immunity through activation of T and NK cells, neoantigen recognition, and increased PD-L1 expression; this immune system stimulation is enhanced in the background of BRCAness/HRDness.[ 12 – 14 , 16 , 89 ]

There is also compelling evidence that mechanisms of resistance to DNA-damaging agents may also play a meaningful role in immunotherapy outcomes.[ 84 , 85 ] For example, defects in BRCA1/2 correlates to higher levels of PD-L1 expression,[ 12 ] and deleterious DDR mutations are frequent in non–small-cell lung cancer (NSCLC), which are associated with improved clinical outcomes in patients treated with PD-(L)1 blockade.[ 83 ] Conversely, it has been shown that tumor-intrinsic PD-L1 can regulate IFN-γ–induced apoptosis, DDR, RT, and chemotherapy resistance, and effects on Ras/Mek/ERK, PI3K/AKT, JAK/STAT,[ 92 – 97 ] which, altogether suggests a predictive role of DDR pathways in ICI response and creates treatment-exploitable immune signaling effects particularly regarding DDR inhibitor-ICI combinations.

DDR-Targeting and Immunotherapy Combinations

The effects of dysfunctional DDR signaling on the immune environment and consequential sensitization to ICIs serves as rationale for combining these with DDR-targeting therapies.[ 98 ] Mechanisms of synergy are based on preclinical data demonstrating that DDR deficiency results in accumulation of unrepaired DNA damage and resultant neoantigens capable of inducing CD8 + T-cell infiltration and activation.[ 86 ] Innate immune response and CD8 + T-cell activation are strongly correlated with favorable clinical response to ICIs, suggesting these DDR-dependent effects may further sensitize clinical response ( Figure 2 ).

Immunotherapy and PARPi

Therapeutic targeting of genomic instability through the use of DDR inhibitors, including PARPi, have been shown to not only induce synthetic lethality in DDR-deficient tumor cells, but also to augment the tumor immune microenvironment through increased TMB and activation of immunostimulatory genes.[ 10 , 18 ] Multiple combination studies have used ICIs and DDR inhibitors, and preliminary efficacy data demonstrate that the combination of DDR-targeting agents with ICIs is a promising cancer treatment strategy[ 18 , 19 ] ( Table 4 ). Combinations of ICIs with DDR-targeted inhibitors, especially those of PARP, have received extensive attention given high rates of intrinsic and acquired resistance, and immune-stimulating properties as the result of DNA repair inhibition. PARPi also upregulates PD-L1 expression,[ 88 , 97 ] likely as the result of DNA-damage–induced IFN-dependent immune activation, thus serving as rationale for combinations with anti-PD-L1 therapies to impinge on the competing immune consequences of PARPi monotherapy.

Breast and ovarian cancer

BRCA1/2 mutations have demonstrated as a predictive biomarker for response to PARPi and ICI therapies, and these are enriched in breast and ovarian carcinoma populations.[ 37 , 40 ] Specifically, BRCA1/2 mutations potentially result in increased immunogenic phenotypes,[ 87 ] suggesting that dual targeting of both DDR and CTLA-4- and/or PD-(L)1–mediated immunosuppression may be an effective strategy for some patients. In BRCA-mutated ovarian cancer, CTLA-4 antibody blockade synergized therapeutically with PARPi, which resulted in immune-mediated tumor clearance and increased long-term survival.[ 99 ] Combination durvalumab and olaparib has demonstrated clinical activity in previously treated, platinum-resistant recurrent ovarian cancer. KEYNOTE-162, investigating the combination of niraparib with pembrolizumab in patients with recurrent ovarian cancer, demonstrated an ORR of 25% and disease control rate (DCR) of 68%; however, subgroup analysis of patients with BRCA mutation revealed an ORR of 45% and DCR of 73%,[ 100 , 101 ] indicating BRCA mutation status might be predictive of positive clinical response to PARPi combined with ICIs.

The phase 2 MEDIOLA basket trial assessed the efficacy and safety of combination olaparib and durvalumab in patients with solid tumors, including ovarian cancer, breast cancer, and gastric cancer ( NCT02734004 ). In germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer, this combination demonstrated an overall response rate (ORR) of 71.9% with a total of 7 out of 32 complete responses, and a DCR of 65.6% at 28 weeks 54 In gBRCAm HER2-negative metastatic breast cancer, the DCR was 80% at 12 weeks and 50% at 28 weeks, with ORR of 63%. Median PFS (mPFS) was 9.2 months and median overall survival (mOS) was 21.5 months. Moreover, patients with no prior line of chemotherapy had higher ORR and longer OS than those with two prior lines (respectively 78% vs 50% for ORR and 21.3 vs 16.9 months for OS).[ 54 ] In the phase 2 TOPACIO trial ( NCT02657889 ), niraparib and pembrolizumab combination therapy has demonstrated clinical benefit in platinum-resistant TNBC, with numerically higher response rates in those with BRCA-mutated TNBC tumors (ORR of BRCAm vs BRCA wild-type, 47% vs 11%).[ 100 , 101 ]

Combination treatments with ICIs and PARPi are currently under intense exploration ( Table 4 ), with encouraging preliminary results. Although the relationship between endogenous or PARPi-induced BRCAness and immunotherapy response is still being investigated, these ongoing clinical trials will help establish the effect of HR deficiency and DDR-targeting therapies on ICI outcomes in BRCA1/2-associated phenotypes.

Prostate cancer

Prostate cancer is inherently sensitive to hormonal therapies; however, approximately 10% to 20% of patients with advanced prostate cancer will develop castration-resistant prostate cancer within 5 years from diagnosis. Primary prostate cancers generally do not harbor targetable genomic alterations; however, approximately 20–25% of metastatic castration-resistant prostate cancer (mCRPC) is associated with DDR signaling defects, including 12.7% with pathogenic BRCA2 germline mutations, as well as other potentially targetable alterations, such as ATM, BRCA1, CDK12, FANCA, RAD51B, and RAD51C. However, response rates to PARPi vary widely and development of resistance remains problematic. The use of ICIs in mCRPC has also shown mixed efficacy; however, defects in mismatch repair, mutations in the exonuclease domain of the DNA POLE, high TMB, and the presence of biallelic loss of CDK12 among others have shown to be predictive biomarkers of response to immunotherapy in prostate cancer.[ 102 ] A subset of patients with mCRPC have a high mutation load because of alterations in mismatch repair genes, MLH1 and MSH2 . Thus, patients with mCRPC with a high mutational burden, particularly as a result from DNA repair defects, may benefit greatly from DDRtargeting agents and ICI combinations. A combination of PARPi and ICIs is actively being investigated in multiple clinical trials ( Table 4 ). Trials such as Keynote-365 have evaluated ICIs plus PARPi in heavily treated patients with mCRCP, and have demonstrated improved PSA response rates, radiologic ORR, DCR, and PFS.

Lung cancer

The PACIFIC trial set the new standard of care for advanced NSCLC with the addition of maintenance durvalumab following chemoradiotherapy[ 103 ]; however, combination with PARPi is being evaluated to increase efficacy both in the first-line and maintenance therapeutic settings, and evaluate therapies to reverse ICI resistance. The KEYLYNK-012 study ( NCT04380636 ) is a phase 3 trial evaluating pembrolizumab alone or in combination with olaparib post-chemoradiotherapy in patients with unresectable, locally advanced stage 3 NSCLC. This combination is also being studied in KEYLYNK-006 (nonsquamous; NCT03976323 ) and KEYLYNK-008 (squamous; NCT03976362 ) as first-line treatment for metastatic NSCLC. The phase 2, biomarker-directed HUDSON study is evaluating the combination of durvalumab in combination with olaparib in patients with NSCLC with HRR defects, and the combination of durvalumab and AZD6738 (ATR inhibitor) in those with ATM deficiency.

In the case of SCLC, most patients respond suboptimally to ICIs despite a relatively high TMB.[ 90 ] Recent studies have shown that targeting DDR promotes T-cell–mediated antitumor immunity in a STING-dependent manner,[ 14 ] setting the stage for potentially increased efficacy of PD-(L)1 inhibitors in patients with lung cancer. Early-phase, small cohort trials support this hypothesis that tumors with inflamed phenotypes as measured by tumor infiltrating CD8 + T cells respond to the combination of durvalumab and olaparib, whereas the ORR for all patients irrespective of inflammatory phenotype is 10.5%; this difference highlights the need for large-scale prospective investigations of predictive biomarkers and therapeutic strategies to address ICI resistance in SCLC.[ 104 ]

Immunotherapy and Other DDR-Targeted Strategies

Targeting of other mediators of DNA damage response and repair pathways is actively being pursued as a strategy to enhance cancer immunotherapies. A preclinical study demonstrated that DNA-damage induced PD-L1 expression by IR or chemotherapy is attenuated by ATR inhibition, suggesting crosstalk between DDR and immune checkpoints, and providing rationale for combination therapy with ATR inhibitors and ICIs.[ 105 ] The ATR inhibitor ceralasertib (AZD6738) was studied in combination with durvalumab in patients with advanced or metastatic melanoma who had previously failed anti-PD-1 therapy, with an ORR of 31.0% and a DCR of 63.3%.[ 106 ] The median duration of response was 8.8 months (range, 3.8–11.7 months). Other clinical trials investigating the combination of ATR inhibitors and ICIs in various cancer types are ongoing ( Table 4 ).

Adavosertib (AZD1775), a highly selective inhibitor of WEE1, was studied in combination with durvalumab in a phase 1 study ( NCT02617277 ) in patients with advanced solid tumors, with preliminary evidence of antitumor activity and DCR for the total cohort of 36%[ 107 ]; a phase 2 study is ongoing based on these promising data. The phase 1b BISCAY trial is a biomarker-directed study in patients with metastatic muscle-invasive bladder cancer; patients with any HR deficiency will receive durvalumab with or without olaparib, and patients with CDKN2A or RB1 deficiency and/or amplifications of CCNE1, MYC, MYCL, or MYCN will receive durvalumab with or with adavosertib.[ 108 ]

In addition to inducing cell cycle arrest, CDK4/6 inhibitors have been found to enhance tumor immunogenicity through increased tumor antigen presentation, enhance T-cell activation, increase tumor PD-L1 expression, and suppress regulatory T-cell proliferation, providing rationale for combinatory regimens of CDK4/6 inhibitors and immunotherapy.[ 109 ] Furthermore, the SCP3-cyclin D1-CDK4/6 axis is activated by the antitumor immune response and facilitates tumor cell resistance to immunotherapy, suggesting that CDK4/6 inhibition may reverse immune escape and promote durable responses to ICIs. Preclinical studies have demonstrated that combination CDK4/6 inhibitors with ICIs and PI3Kα resulted in complete and durable regression in established xenograft mouse models of human TNBC.[ 110 ] CDK4/6 inhibitors in combination with ICIs are being investigated in clinical trials for various cancers, including breast cancer, head and neck squamous cell carcinoma (HNSCC), NSCLC, and hepatic cancers.

ATM inhibition has be shown to increase IFN signaling and sensitize pancreatic cancer to ICI therapy,[ 111 ] and ATM pathway inhibition has been reported to activate innate immunity in ARID1A-deficient cancers and enhance immune activation following PD-L1 blockade.[ 112 ] ATM inhibitors (M3541 and AZD0156) are currently in early-phase clinical trials for treatment of solid tumors.

DNA-PK has been reported to activate STING-independent DNA sensing resulting in robust and broad Th1 immune activation[ 113 ]; this result suggests that targeted DDR inhibition may synergistically increase immunotherapy efficacy though DNA-PK–dependent immune augmentation. The DNA-PK inhibitor nedisertib is being studied in combination with avelumab with or without RT in patients with advanced solid tumors ( NCT03724890 ).

CHK1 inhibition has been found to activate the cGAS/STING pathway and increase tumor PD-L1 expression in SCLC, which significantly enhances the efficacy of ICIs.[ 14 ] This study also identified MYC as a biomarker of CHK1 response, suggesting that combination strategies involving CHK1 inhibitors might be effective in cancers with MYC amplification or overexpression. These preclinical studies indicate the need to explore this combination in clinical trials.

Overall, for combinations of DDR-targeting therapy and immunotherapy, biomarker-directed preclinical and clinical studies to identify mechanisms of response and resistance is imperative. Most early-phase and ongoing clinical trials have been performed with unselected patients; however, more recent trials have focused on predictive DDR markers. For example, ARID1A, ATM, ATRX BRCA1/2, CDK12, CH1, CHK2, CCNE1, MYC, MRE11, MSH2, PARP1, PI3CA, POLD1, PPP2P2A, PTEN, RAD51B, XRCC2, and MMR status are a focus of ongoing clinical trials assessing predictive markers for DDR and immunotherapy combinations ( NCT03842228 , NCT02546661 ). These studies will help decipher clinical utility of current DDR and ICI combinations, and perhaps identify novel indications of lesser explored DDR targets for precise, patient-, tissue-, and cancer-specific therapeutic targets.

DISCUSSION AND FUTURE CONSIDERATIONS

Studies of the molecular underpinnings of DDR signaling and the interconnectivity with various cellular processes that alter oncogenesis and anticancer immunity have revealed a complex landscape of DDR pathways, uncovering new ways to personalize cancer therapy for each individual patient based on specific tumor cell genetic and immunologic signatures. Targeting DDR pathways is an effective method of treating certain cancers, for instance with the use of PARPi in HR-deficient (i.e., BRCA1/2 mutated) cancers. Increasing responsiveness and direction of response to current PARP and other DDR inhibitors is now a major focus. Pharmacologic induction of HRD phenotypes in otherwise HR-proficient tumors is also an area of recent exploration. For example, molecularly targeted agents such as mTOR or PI3K inhibitors may be able to create BRCAness or HRDness, and this area requires further exploration and clinical development. To build on the success of DDR-targeted monotherapies and overcome the clinical conundrum of eventual drug resistance, it is important to recognize opportunities to incorporate biomarker-directed treatment decision making and the use of combination strategies.

There is preclinical and mechanistic rationale for combining DDR-targeting agents with immunotherapy, with early-phase clinical trials demonstrating very promising antitumor effects. For example, the combination of olaparib and durvalumab in BRCA1/2-mutated ovarian cancer, niraparib and pembrolizumab in platinum-resistant ovarian cancer, and PD-(L)1 blockade for cancers with MMR deficiency may represent significant advances in cancer treatment paradigms. The combination of PARPi with ICIs is also being explored in HNSCC, soft tissue sarcoma, renal cancer, gastric cancer, and lymphoma, among others. However, many questions remain regarding optimal use in the first-line and maintenance settings, potential overlapping toxicities, the relationship between DDR gene alterations and known biomarkers of ICIs, and lack of bonified biomarkers to guide targeted agent selection and immunotherapy combinations.

More understanding of DDR activity in mitigating genomic instability and associated effects on innate and adaptive antitumor immunity is required to maximize clinical benefit of targeted therapies. Given the diversity of immunologic actions of DDR signaling, it will also be important to carefully select and develop DDR-immunotherapy combinations to avoid deleterious DDR signaling inhibition and attenuation of antitumor immunity. Recent preclinical and biomarker-directed clinical studies have made substantial advances in these areas; however, as our understanding of the relationship between tumor-intrinsic gene alterations and antitumor immunity develops, additional basic and translational investigations will be required to identify mechanisms of resistance and advance novel clinical strategies for DDR and immunotherapy approaches.

Conflict of Interest: Eddy Yang serves on the advisory boards of AstraZeneca, Bayer, Clovis, and Strata Oncology and receives research support to institution from Eli Lilly, Novartis, and Puma Biotechnologies. Curtis Clark has no disclosures.

References

1 Lord CJ Ashworth A The DNA damage response and cancer therapy Nature 2012 481 287 294 22258607 10.1038/nature10760

2 Burrell RA McGranahan N Bartek J Swanton C The causes and consequences of genetic heterogeneity in cancer evolution Nature 2013 501 338 345 24048066 10.1038/nature12625

3 Klinakis A Karagiannis D Rampias T Targeting DNA repair in cancer: current state and novel approaches Cell Mol Life Sci 2020 77 677 703 31612241 10.1007/s00018-019-03299-8 PMC11105035

4 Lord CJ Ashworth A PARP inhibitors: synthetic lethality in the clinic Science 2017 355 1152 1158 28302823 10.1126/science.aam7344 PMC6175050

5 Tung NM Robson ME Ventz S TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes J Clin Oncol 2020 38 36 4274 4282 33119476 10.1200/JCO.20.02151

6 Ashworth A A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 2008 26 3785 3790 18591545 10.1200/JCO.2008.16.0812

7 Sato H Niimi A Yasuhara T DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells Nat Commun 2017 8 1751 29170499 10.1038/s41467-017-01883-9 PMC5701012

8 Samstein RM Lee CH Shoushtari AN Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nat Genet 2019 51 202 206 30643254 10.1038/s41588-018-0312-8 PMC6365097

9 Yarchoan M Hopkins A Jaffee EM Tumor mutational burden and response rate to PD-1 inhibition N Engl J Med 2017 377 2500 2501 29262275 10.1056/NEJMc1713444 PMC6549688

10 Ablasser A Goldeck M Cavlar T cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING Nature 2013 498 380 384 23722158 10.1038/nature12306 PMC4143541

11 Ribas A Wolchok JD Cancer immunotherapy using checkpoint blockade Science 2018 359 1350 1355 29567705 10.1126/science.aar4060 PMC7391259

12 Strickland KC Howitt BE Shukla SA Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer Oncotarget 2016 7 13587 13598 26871470 10.18632/oncotarget.7277 PMC4924663

13 Heijink AM Talens F Jae LT BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity Nat Commun 2019 10 100 30626869 10.1038/s41467-018-07927-y PMC6327059

14 Sen T Rodriguez BL Chen L Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer Cancer Discov 2019 9 646 661 30777870 10.1158/2159-8290.CD-18-1020 PMC6563834

15 Fridman WH Zitvogel L Sautès–Fridman C Kroemer G The immune contexture in cancer prognosis and treatment Nat Rev Clin Oncol 2017 14 717 734 28741618 10.1038/nrclinonc.2017.101

16 Nolan E Savas P Policheni AN Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer Sci Transl Med 2017 9 4922 10.1126/scitranslmed.aal4922 PMC5822709 28592566

17 Hanahan D Hallmarks of cancer: new dimensions Cancer Discov 2022 12 31 46 35022204 10.1158/2159-8290.CD-21-1059

18 Lamberti G Andrini E Sisi M Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication Future Oncol 2020 16 1751 1766 32539551 10.2217/fon-2020-0215

19 Brown JS O'Carrigan B Jackson SP Yap TA Targeting DNA repair in cancer: beyond PARP inhibitors Cancer Discov 2017 7 20 37 28003236 10.1158/2159-8290.CD-16-0860 PMC5300099

20 Blackford AN Jackson SP. ATM ATR, and DNA-PK: the trinity at the heart of the DNA damage response Mol Cell 2017 66 801 817 28622525 10.1016/j.molcel.2017.05.015

21 Tubbs A Nussenzweig A Endogenous DNA damage as a source of genomic instability in cancer Cell 2017 168 644 656 28187286 10.1016/j.cell.2017.01.002 PMC6591730

22 Robinson D Van Allen EM Wu YM Integrative clinical genomics of advanced prostate cancer Cell 2015 161 1215 1228 26000489 10.1016/j.cell.2015.05.001 PMC4484602

23 Ellisen LW PARP inhibitors in cancer therapy: promise, progress, and puzzles Cancer Cell 2011 19 165 167 21316599 10.1016/j.ccr.2011.01.047 PMC3070420

24 Pilie PG Tang C Mills GB Yap TA State-of-the-art strategies for targeting the DNA damage response in cancer Nat Rev Clin Oncol 2019 16 81 104 30356138 10.1038/s41571-018-0114-z PMC8327299

25 O'Connor MJ Targeting the DNA damage response in cancer Mol Cell 2015 60 547 560 26590714 10.1016/j.molcel.2015.10.040

26 Farmer H McCabe N Lord CJ Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 917 921 15829967 10.1038/nature03445

27 Golan T Hammel P Reni M Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer N Engl J Med 2019 381 317 327 31157963 10.1056/NEJMoa1903387 PMC6810605

28 Litton JK Rugo HS Ettl J Talazoparib in patients with advanced breast cancer and a germline BRCA mutation N Engl J Med 2018 379 753 763 30110579 10.1056/NEJMoa1802905 PMC10600918

29 Robson M Im SA Senkus E Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial N Engl J Med 2017 377 523 533 28578601 10.1056/NEJMoa1706450

30 Litton JK Hurvitz SA Mina LA Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial Ann Oncol 2020 31 1526 1535 32828825 10.1016/j.annonc.2020.08.2098 PMC10649377

31 Nowsheen S Cooper T Stanley JA Yang ES Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells PLoS One 2012 7 e46614 23071597 10.1371/journal.pone.0046614 PMC3469581

32 Verma N Vinik Y Saroha A Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis Sci Adv 2020 6 1 18 10.1126/sciadv.aba8968 PMC7442484 32937365

33 Li Y Wang Y Zhang W BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression Sci Rep 2021 11 4774 33637776 10.1038/s41598-021-82990-y PMC7910492

34 Stringer-Reasor EM May JE Olariu E An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer Breast Cancer Res 2021 23 30 33663560 10.1186/s13058-021-01408-9 PMC7934554

35 Oaknin A Oza AM Lorusso D Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: the effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety Cancer Med 2021 10 7162 7173 34549539 10.1002/cam4.4260 PMC8525125

36 Poveda A Floquet A Ledermann JA Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol 2021 22 620 631 33743851 10.1016/S1470-2045(21)00073-5

37 Swisher EM Kwan TT Oza AM Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Nat Commun 2021 12 2487 33941784 10.1038/s41467-021-22582-6 PMC8093258

38 Kaufman B Shapira-Frommer R Schmutzler RK Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol 2015 33 244 250 25366685 10.1200/JCO.2014.56.2728 PMC6057749

39 Swisher EM Lin KK Oza AM Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Lancet Oncol 2017 18 75 87 27908594 10.1016/S1470-2045(16)30559-9

40 Kristeleit R Lisyanskaya A Fedenko A Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial Lancet Oncol 2022 23 465 478 35298906 10.1016/S1470-2045(22)00122-X

41 Tutt ANJ Garber JE Kaufman B Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer N Engl J Med 2021 384 2394 2405 34081848 10.1056/NEJMoa2105215 PMC9126186

42 Somlo G Frankel PH Arun BK Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083 Clin Cancer Res 2017 23 4066 4076 28356425 10.1158/1078-0432.CCR-16-2714 PMC5540749

43 Han H Liu MC Hamilton E Abstract P31103 Pilot neoadjuvant study of niraparib in HER2negative BRCAmutated resectable breast cancer Cancer Res 2020 80(4_Supplement)P31103

44 Severson TM Wolf DM Yau C The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting Breast Cancer Res 2017 19 99 28851423 10.1186/s13058-017-0861-2 PMC5574249

45 Hussain M Mateo J Fizazi K Survival with olaparib in metastatic castration-resistant prostate cancer N Engl J Med 2020 383 2345 2357 32955174 10.1056/NEJMoa2022485

46 Carreira S Porta N Arce-Gallego S Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B Trial Cancer Discov 2021 11 2812 2827 34045297 10.1158/2159-8290.CD-21-0007 PMC9414325

47 Mateo J Porta N Bianchini D Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Lancet Oncol 2020 21 162 174 31806540 10.1016/S1470-2045(19)30684-9 PMC6941219

48 Mateo J Carreira S Sandhu S DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 2015 373 1697 1708 26510020 10.1056/NEJMoa1506859 PMC5228595

49 Abida W Patnaik A Campbell D Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration J Clin Oncol 2020 38 3763 3772 32795228 10.1200/JCO.20.01035 PMC7655021

50 Loehr A Patnaik A Campbell D Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 Study Clin Cancer Res 2021 27 6677 6686 34598946 10.1158/1078-0432.CCR-21-2199 PMC8678310

51 Abida W Campbell D Patnaik A Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the Phase II TRITON2 Study Clin Cancer Res 2020 26 2487 2496 32086346 10.1158/1078-0432.CCR-20-0394 PMC8435354

52 de Bono JS Mehra N Scagliotti GV Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial Lancet Oncol 2021 22 1250 1264 34388386 10.1016/S1470-2045(21)00376-4

53 Murai J Huang S-yN, Das BB Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 2012 72 5588 5599 23118055 10.1158/0008-5472.CAN-12-2753 PMC3528345

54 Domchek S Postel-Vinay S Im SA 1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA) updated results in patients (pts) with germline BRCAmutated (gBRCAm) metastatic breast cancer (MBC) Ann Oncol 2019 30(suppl_5)v477

55 Golan T Hammel P Reni M Overall survival from the phase 3 POLO trial Maintenance olaparib for germline BRCAmutated metastatic pancreatic cancer J Clin Oncol 2021 39(3_suppl)378

56 Bendell J O'Reilly EM Middleton MR Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer Ann Oncol 2015 26 804 811 25573533 10.1093/annonc/mdu581 PMC8890482

57 Bang YJ Xu RH Chin K Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol 2017 18 1637 1651 29103871 10.1016/S1470-2045(17)30682-4

58 Mo M Yang J Zhu X Zhu J Use of olaparib in patients with advanced gastric cancer Lancet Oncol 2018 19 e75 29413476 10.1016/S1470-2045(18)30023-8

59 Lin KK Harrell MI Oza AM BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma Cancer Discov 2019 9 210 219 30425037 10.1158/2159-8290.CD-18-0715

60 Pettitt SJ Krastev DB Brandsma I Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance Nat Commun 2018 9 1849 29748565 10.1038/s41467-018-03917-2 PMC5945626

61 Gogola E Duarte AA de Ruiter JR Selective loss of PARG restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality Cancer Cell 2018 33 1078 1093.e12 29894693 10.1016/j.ccell.2018.05.008

62 Nesic K Kondrashova O Hurley RM Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma Cancer Res 2021 81 4709 4722 34321239 10.1158/0008-5472.CAN-21-0774 PMC12593227

63 Kondrashova O Topp M Nesic K Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma Nat Commun 2018 9 3970 30266954 10.1038/s41467-018-05564-z PMC6162272

64 Collot T Niogret J Carnet M PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: four case reports Mol Med Rep 2021 23 75 33236159 10.3892/mmr.2020.11713

65 Mo W Liu Q Lin CC mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer Clin Cancer Res 2016 22 1699 712 26546619 10.1158/1078-0432.CCR-15-1772 PMC4858320

66 Sun C Fang Y Yin J Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers Sci Transl Med 2017 9:eaal5148 10.1126/scitranslmed.aal5148 PMC5919217 28566428

67 Li L Karanika S Yang G Androgen receptor inhibitorinduced “BRCAness” and PARP inhibition are synthetically lethal for castrationresistant prostate cancer Sci Signal 2017 10:eaam7479 10.1126/scisignal.aam7479 PMC5855082 28536297

68 Kanakkanthara A Hou X Ekstrom TL Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma Cancer Res 2022 82 307 319 34810199 10.1158/0008-5472.CAN-21-0732 PMC8770599

69 Shiloh Y Ziv Y The ATM protein kinase: regulating the cellular response to genotoxic stress, and more Nat Rev Mol Cell Biol 2013 14 197 210 23847781

70 Ma CX Ellis MJ Petroni GR A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer Breast Cancer Res Treat 2013 137 483 492 23242585 10.1007/s10549-012-2378-9 PMC3539064

71 Sausville E Lorusso P Carducci M Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors Cancer Chemother Pharmacol 2014 73 539 549 24448638 10.1007/s00280-014-2380-5 PMC4486055

72 Wehler T Thomas M Schumann C A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer Lung Cancer 2017 108 212 216 28625637 10.1016/j.lungcan.2017.03.001

73 Al-Ahmadie H Iyer G Hohl M Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy Cancer Discov 2014 4 1014 1021 24934408 10.1158/2159-8290.CD-14-0380 PMC4155059

74 Yang ES Deutsch E Mehmet A A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma Radiother Oncol 2021 157 203 209 33577866 10.1016/j.radonc.2021.01.032

75 Hong DS Moore K Patel M Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma Clin Cancer Res 2018 24 3263 3272 29643063 10.1158/1078-0432.CCR-17-3347 PMC6050086

76 Esashi F Christ N Gannon J CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair Nature 2005 434 598 604 15800615 10.1038/nature03404

77 Geenen JJJ Schellens JHM Molecular pathways: targeting the protein kinase Wee1 in cancer Clin Cancer Res 2017 23 4540 4544 28442503 10.1158/1078-0432.CCR-17-0520

78 Bridges KA Hirai H Buser CA MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells Clin Cancer Res 2011 17 5638 5648 21799033 10.1158/1078-0432.CCR-11-0650 PMC3167033

79 Aarts M Sharpe R Garcia-Murillas I Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1 Cancer Discov 2012 2 524 539 22628408 10.1158/2159-8290.CD-11-0320

80 Chera BS Sheth SH Patel SA Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma Cancer 2021 127 4447 4454 34379792 10.1002/cncr.33789

81 Chen DS Mellman I Elements of cancer immunity and the cancer–immune set point Nature 2017 541 321 330 28102259 10.1038/nature21349

82 Sharma P Allison James P Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 2015 161 205 214 25860605 10.1016/j.cell.2015.03.030 PMC5905674

83 Ricciuti B Recondo G Spurr LF Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer Clin Cancer Res 2020 26 4135 4142 32332016 10.1158/1078-0432.CCR-19-3529

84 Teo MY Seier K Ostrovnaya I Alterations in DNA damage response and repair genes as potential marker of clinical benefit From PD-1/PD-L1 blockade in advanced urothelial cancers J Clin Oncol 2018 36 1685 1694 29489427 10.1200/JCO.2017.75.7740 PMC6366295

85 Le DT Durham JN Smith KN Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 2017 357 409 413 28596308 10.1126/science.aan6733 PMC5576142

86 McGranahan N Furness AJS Rosenthal R Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Science 2016 351 1463 1469 26940869 10.1126/science.aaf1490 PMC4984254

87 Wen WX Leong C-O Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer PLoS One 2019 14 e0215381 31022191 10.1371/journal.pone.0215381 PMC6483182

88 Jiao S Xia W Yamaguchi H PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression Clin Cancer Res 2017 23 3711 3720 28167507 10.1158/1078-0432.CCR-16-3215 PMC5511572

89 Reislander T Groelly FJ Tarsounas M DNA damage and cancer immunotherapy: a STING in the tale Mol Cell 2020 80 21 28 32810436 10.1016/j.molcel.2020.07.026

90 Sun W Zhang Q Wang R Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications Front Oncol 2021 11 648687 34026622 10.3389/fonc.2021.648687 PMC8137908

91 Brown JS O'Carrigan B Jackson SP Yap TA Targeting DNA repair in cancer: beyond PARP inhibitors Cancer Discov 2017 7 20 37 28003236 10.1158/2159-8290.CD-16-0860 PMC5300099

92 Tu X Qin B Zhang Y PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy Mol Cell 2019 74 1215 1226.e4 31053471 10.1016/j.molcel.2019.04.005 PMC6737939

93 Escors D Gato-Canas M Zuazo M The intracellular signalosome of PD-L1 in cancer cells Signal Transduct Target Ther 2018 3 26 30275987 10.1038/s41392-018-0022-9 PMC6160488

94 Chang CH Qiu J O'Sullivan D Metabolic competition in the tumor microenvironment is a driver of cancer progression Cell 2015 162 1229 1241 26321679 10.1016/j.cell.2015.08.016 PMC4864363

95 Clark CA Gupta HB Sareddy G Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma Cancer Res 2016 76 6964 6974 27671674 10.1158/0008-5472.CAN-16-0258 PMC5228566

96 Gupta HB Clark CA Yuan B Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer Signal Transduct Target Ther 2016 1 16030 28798885 10.1038/sigtrans.2016.30 PMC5547561

97 Clark CA Yang ES Harnessing DNA repair defects to augment immune-based therapies in triple-negative breast cancer Front Oncol 2021 11 703802 34631532 10.3389/fonc.2021.703802 PMC8497895

98 Vikas P Borcherding N Chennamadhavuni A Garje R Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors Front Oncol 2020 10 570 32457830 10.3389/fonc.2020.00570 PMC7228136

99 Higuchi T Flies DB Marjon NA CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer Cancer Immunol Res 2015 3 1257 1268 26138335 10.1158/2326-6066.CIR-15-0044 PMC4984269

100 Vinayak S Tolaney SM Schwartzberg L Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer JAMA Oncol 2019 5 1132 1140 31194225 10.1001/jamaoncol.2019.1029 PMC6567845

101 Konstantinopoulos PA Waggoner S Vidal GA Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma JAMA Oncol 2019 5 1141 1149 31194228 10.1001/jamaoncol.2019.1048 PMC6567832

102 Ottini A Sepe P Beninato T Biomarker-driven immunotherapy for precision medicine in prostate cancer Per Med 2022 19 51 66 34873959 10.2217/pme-2021-0079

103 Spigel DR Faivre-Finn C Gray JE Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer J Clin Oncol 2022 40 1301 1311 35108059 10.1200/JCO.21.01308 PMC9015199

104 Thomas A Vilimas R Trindade C Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase II study J Thorac Oncol 2019 14 1447 1457 31063862 10.1016/j.jtho.2019.04.026 PMC6660419

105 Sun LL Yang RY Li CW Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing Am J Cancer Res 2018 8 1307 1316 30094103 PMC6079156

106 Kim R Kwon M An M Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy Ann Oncol 2022 33 193 203 34710570 10.1016/j.annonc.2021.10.009

107 Patel MR Falchook GS Wang JS-Z Openlabel multicenter phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors J Clin Oncol 2019 37(15_suppl):2562–2562 10.1007/s11523-024-01110-8 PMC11762568 39560862

108 Powles T Carroll D Chowdhury S An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer Nat Med 2021 27 793 801 33941921 10.1038/s41591-021-01317-6

109 Deng J Wang ES Jenkins RW CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation Cancer Discov 2018 8 216 233 29101163 10.1158/2159-8290.CD-17-0915 PMC5809273

110 Teo ZL Versaci S Dushyanthen S Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple-negative breast cancer Cancer Res 2017 77 6340 6352 28947417 10.1158/0008-5472.CAN-17-2210

111 Zhang Q Green MD Lang X Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy Cancer Res 2019 79 3940 3951 31101760 10.1158/0008-5472.CAN-19-0761 PMC6684166

112 Wang L Yang L Wang C Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors J Clin Invest 2020 130 5951 5966 33016929 10.1172/JCI130445 PMC7598069

113 Burleigh K Maltbaek JH Cambier S Human DNAPK activates a STINGindependent DNA sensing pathway Sci Immunol 2020 5:eaba4219 10.1126/sciimmunol.aba4219 PMC7081723 31980485